Tesofensine is the weight loss compound that pharmaceutical companies accidentally discovered while trying to treat Parkinson's—a triple monoamine reuptake inhibitor that simultaneously boosts dopamine, norepinephrine, and serotonin to produce what might be the most powerful appetite suppression and metabolic acceleration available in a single oral compound. The Phase 2 trial data was genuinely shocking—up to 12.8% body weight loss at the 1.0mg dose over 24 weeks, which rivaled the best GLP-1 results without the nausea and GI side effects that make semaglutide miserable for some people. What makes it mechanistically different from GLP-1 drugs is that it works through your brain's reward and satiety circuits rather than your gut—boosting dopamine means you don't just eat less, you actually feel good eating less, which is why adherence tends to be easier. The triple reuptake inhibition also delivers mood enhancement, improved focus, and sustained energy that most weight loss compounds can't touch. It didn't get FDA approval because higher doses caused cardiovascular concerns (elevated heart rate and blood pressure), but at 0.25-0.5mg those effects are manageable—and it's currently being developed in Denmark as Tesomet for Prader-Willi syndrome, so the clinical story isn't over.
Applications: Weight Loss, Metabolism Support, Mood Support
Written by Peppa at Peptide Upside — the peptide lifestyle guide. Research, calculate, and track your peptide journey.